CHICAGO | The aromatase inhibitor exemestane reduces the risk of invasive breast cancer by 65% in high-risk postmenopausal women, according to a large phase III, placebo-controlled trial led and coordinated by Canada’s NCIC Clinical Trials Group.
Drug indicated for reducing the of developing skeletal-related events in patients with bone metastases from breast cancer, prostate cancer, non-small cell lung cancer and other solid tumours.
